Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences Inc (NQ: RXDX )

111.79 +2.11 (+1.92%)
Streaming Delayed Price Updated: 9:43 AM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prometheus Biosciences Inc

Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials
Prometheus Biosciences, Inc. (NASDAQ: RXDX) is engaged as a clinical-stage biotechnology company, which is focused on the research, development and 
Via Spotlight Growth
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences to Participate at November Healthcare Conferences
From Prometheus Biosciences
Via Globe NewsWire
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
From Prometheus Biosciences
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.